Skip to content
Screener
Q3 '26Q2 '26Q1 '26Q4 '25Q3 '25
$0—$0—$20M—————
$34.32M+54.0%$51.41M+127%$32.72M+67.2%$30.26M+75.9%$22.28M+43.3%
$9.77M—$9.39M+37.8%$11.5M+52.6%————
$44.09M+47.0%$60.81M+106%$44.22M+63.1%$38.51M+63.7%$29.99M+38.6%
-$44.09M-47.0%-$60.81M-106%-$24.22M+10.7%-$38.51M-63.7%-$29.99M-38.6%
$3.85M+25.8%$4.19M+51.6%$4.36M+43.1%$4.75M+34.0%$3.06M-25.4%
-$40.24M-49.4%-$56.62M-112%-$19.86M+17.5%-$33.76M-69.0%-$26.93M-53.5%
-$0.84-18.3%-$1.19-58.7%-$0.42+38.2%-$0.71-492%-$0.71-42.0%
-$43.89M-47.6%-$60.59M-107%-$23.99M+10.7%-$38.24M-64.4%-$29.73M-38.8%
-$44.09M-47.0%-$60.81M-106%-$24.22M+10.7%-$38.51M-63.7%-$29.99M-38.6%

FAQ

Is Rapport Therapeutics, Inc. profitable?
Rapport Therapeutics, Inc. is not currently profitable: it reported a net loss of $150.5M over the trailing twelve months.
What is Rapport Therapeutics, Inc.'s earnings per share?
Rapport Therapeutics, Inc.'s diluted EPS over the trailing twelve months is $-3.16.
Where does Rapport Therapeutics, Inc.'s income statement data come from?
Every line is extracted from Rapport Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.